SecBot SecBot
SECBOTREPLAY Home › Report › NRXP

NRXP · NRx Pharmaceuticals announced FDA approval of its ANDA for…

NRX Pharmaceuticals, Inc. · 8-K filed Nov 2, 2026 at 08:06 ET

At the news

BULLISHIMPACT 6/10

8-K filed Nov 2, 2026 at 08:06 ET

NRx Pharmaceuticals announced FDA approval of its ANDA for Preservative-Free Ketamine, ahead of the November 10, 2026 GDUFA goal date. The product is a preservative-free formulation of ketamine manufactured in the U.S. with Nephron Pharmaceuticals, addressing a drug shortage. The company has commercial supply on hand and can now label and supply hospitals and clinics.

  • FDA approved NRx's ANDA for Preservative-Free Ketamine on October 30, 2026, ahead of the November 10, 2026 GDUFA goal date.
  • The product contains no benzethonium chloride (BZT), a preservative not designated as GRAS by the FDA.
  • Ketamine injection has been in short supply since 2018 and is on the FDA drug shortage list.
  • NRx has manufactured commercial supply on hand and can now label and supply American hospitals and clinics.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access